Purchase this article with an account.
H. Elsner, S.H. M. Liew, C. Klatt, P. Hamilton, J. Marshall, E. Pörksen, H. Laqua, R. Brinkmann, R. Birngruber, J. Roider; Selective–Retina–Therapy (SRT) Multicenter Clinical Trial: 6 Month Results in Patients With Diabetic Maculopathy . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1463.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: Selective–Retina–Therapy (SRT) is currently investigated in a multicenter, prospective, clinical trial for patients with focal diabetic maculopathy (DMP). In comparison to conventional Argon laser treatment, SRT uses a train of µs laser pulses and selectively damages RPE–cells while sparing retinal structures. This clinical trial is designed to evaluate the visual and morphologic outcome of patients with focal DMP treated with SRT. Methods: 60 eyes of 60 patients with focal DMP and visual acuity (VA) of > 20/100 were recruited into the study. Standardized VA assessment using ETDRS charts, fundus photography, fluorescein angiography (FA) (graded by 2 independent masked observers) and optical coherence tomography (Humphrey/Zeiss OCT III) were performed at each visit. Patients were treated with SRT using a frequency doubled Q–switched Nd:YLF laser (527 nm). Each laser exposition contains a train of 30 pulses, each with a duration of 1,7 µs, at a repetition rate of 100 Hz. Follow–up examinations were performed after 3 and 6 months. Results: The SRT laser lesions were not visible ophthalmoscopically during treatment, but were detectable by FA. At present, 53 patients have completed the 6 months follow–up. Median foveal retinal thickness, measured by OCT, was at baseline 244 µm and 230 µm at 6 months. Moreover the maximum retinal thickness measured by radial OCT–scans in the treated edematous macula area decreased from 351 µm at baseline to 330 µm after 6 months. FA leakage decreased in 31,1%, remained stable in 52,1% and increased in 15,8% of the patients after 6 months. VA results at 6 months showed that 39,6% of patients had an improvement of greater than 1 line, 49,1 % demonstrated a stabilization of VA within + 1 line and 11,3 % had a reduction of greater than 1 line. Conclusions: SRT is a safe and effective laser treatment for focal DMP. It leads to a reduction of retinal thickness measured by OCT and leakage on FA. 88,7 % of patients have stable or improved VA after 6 months in this study . It offers the potential for earlier treatment and the possibility of treating closer to the fovea without side effects associated with conventional argon laser treatment.
This PDF is available to Subscribers Only